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Obstructive sleep apneaAbstract Allergic rhinitis (AR) related inflammation might worsen the severity of
obstructive sleep apnea (OSA), however, the relationship between the two disorders
remains controversial. Our aim was to determine the prevalence of AR and atopic
markers in OSA. This cross-sectional study recruited participants with sleep-
related complaints referred to a sleep center from February 2013 to June 2014.
The diagnosis of OSA was based on the Berlin questionnaire (BQ) followed by confir-
matory polysomnography (PSG). The diagnosis of AR was made via focused history
and clinical examination and was confirmed by measuring atopic markers. OSA
was diagnosed in 97 out of 157 adults attending the sleep clinic (61.8%). There
was a high prevalence of AR (52.6%) among OSA individuals. This was not signifi-
cantly different from the frequency in the non-OSA individuals (p = 0.5). Elevated
total immunoglobulin E (IgE; >100 K/lL), eosinophil count, and positive Phadiatop
tests were found in individuals with OSA to be 37.1%, 11.3%, and 41.2%, respectively.
Individuals without OSA have shown similar percentages. In our cohort, there was no80215,
38 G. Gadi et al.significant difference in frequency of AR and atopy among participants with OSA
compared to those without OSA.
 2016 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Obstructive sleep apnea (OSA) refers to repeated
episodes of halted respiration during sleep, despite
a continuous effort to breathe [1]. Clinically, OSA
is characterized by excessive daytime sleepiness,
disruptive snoring, and nocturnal hypoxemia. This
condition is a common sleep-breathing disorder
affecting approximately 4.0% of males and 2.0%
of females of middle age in the developed world
[1]. Many studies have shown that OSA is a signifi-
cant source of morbidity and mortality; it is associ-
ated with serious health consequences, mostly
afflicting the cardiovascular and cerebrovascular
systems [1]. In addition to excessive daytime
sleepiness, people with OSA have subsequent
decreased functional ability, which could lead to
motor vehicle accidents [1].
The mechanism of OSA is not well understood,
but is mostly attributed to mechanical upper air-
way disruption (airway narrowing or collapse),
leading to increased airflow resistance. Accord-
ingly, several reports have hypothesized that aller-
gic rhinitis (AR) may influence the occurrence of
OSA through inflammatory elements that induce
nasal congestion and subsequently nasal obstruc-
tion [2]. In addition, the high nasal resistance sec-
ondary to nasal obstruction leads to a more
negative intraluminal pressure in the lower airways
that may promote partial or intermittent collapse
of the pharynx, thus increasing the risk of OSA. This
hypothesis is strengthened by the beneficial effect
of intranasal corticosteroid in OSA and rhinitis [6].
Several studies have proposed a link between AR
and OSA. Recently, a Turkish study reported that
23.0% of OSA patients had AR [3], whereas several
European studies have revealed variable rates [4].
We also recently reported that approximately half
of OSA patients in a pilot study had AR, regardless
of the severity of sleep apnea [5]. Furthermore,
several clinical trials investigating the effect of
treating AR in OSA patients found very promising
outcomes. In particular, by reducing levels of
inflammatory mediators, AR treatment may
improve the severity of OSA, the quality of sleep,
and daytime somnolence [6]. These findings illus-
trate a possible link between OSA and AR, and also
suggest a role for allergic inflammatory mediators(e.g., eosinophils) in the development and progres-
sion of sleep-disordered breathing. Additionally,
other atopic diseases, such as bronchial asthma
(BA) and atopic dermatitis, have been implicated
in sleep-disordered breathing, mostly among chil-
dren [7]. This significant finding sheds light on the
potential role of allergic sensitization (atopy) in
the pathophysiology of OSA.
Individuals with atopy are usually identified
based on the presence of allergic diseases such as
asthma, AR, allergic conjunctivitis, food allergy,
and eczema [8]. Allergic sensitization to allergens
is classically confirmed by an in vivo skin-prick test
(SPT) or an in vitro assay for specific serum
immunoglobulin E (IgE) antibodies [8]. Total IgE
and peripheral eosinophils have also been estab-
lished in the literature as nonspecific markers of
atopy; however, their diagnostic value is limited [9].
In addition to a lack of local data, the relation-
ship between AR and OSA remains controversial in
the literature. Furthermore, the association
between atopy and OSA is not well established in
the adult population. Therefore, the present study
aimed to determine the prevalence of atopy in gen-
eral and of AR in particular among adult OSA
patients referred to a university-based sleep cen-
ter. This is a continuation of a previously small
pilot study addressing the relation between AR
and OSA (5), as it is felt that the subject has not
been fully evaluated. Therefore a relatively larger
study is needed to address the possible association
and hence this study.
2. Materials and methods
In this cross-sectional study, all participants with
sleep disorders who were referred to the sleep
clinic at King Abdulaziz University Hospital in Jed-
dah, Saudi Arabia from February 2013 to June
2014 were recruited. Hospital ethics committee
approval was obtained, and written informed con-
sent was requested from all participants. The study
end points were estimates of the prevalence of
atopy and AR among OSA patients.
Individuals who refused to participate or to com-
plete the requirements of the study were
excluded. The study was conducted in two stages.
In Stage 1, each participant was interviewed and
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collected included demographic data, history of
comorbidities, symptoms of atopy and AR, the risk
of OSA determined using the Berlin questionnaire
(BQ) as a screening tool [10], and the propensity
for daytime sleepiness determined using the
Epworth sleepiness scale (ESS) [11]. These assess-
ments were followed by a nasal examination to
detect local signs of AR. Each participant was then
evaluated for atopy by measuring the total serum
level of IgE, the total eosinophil count, and the
levels of serum IgE antibodies specific to common
allergens.
In Stage 2, all participants classified as at high
risk for OSA based on the BQ underwent confirma-
tory overnight polysomnography (PSG). PSG type 1
is considered as the gold standard diagnostic test
for OSA [12]. The apnea-hypopnea index (AHI),
which is the average number of episodes of apnea
and hypopnea per hour of sleep, was also calculated
prior to the diagnosis of OSA [13]. Apnea and hypop-
nea events were defined according to the criteria of
the American Academy of Sleep Medicine [14]. More
specifically, OSA is said to exist when the AHI is
greater than five, coupled with symptoms or signs
of disturbed sleep, or when the AHI is 15, regard-
less of symptoms [13]. OSA severity was classified as
mild, moderate, or severe based on AHI values of 5,
15, and 30, respectively [14].
2.1. Establishing the diagnosis of atopy
Atopy was evaluated based on the presence of
allergic diseases and screening for sensitization to
common inhalant allergens, as reflected by specific
IgE antibodies in the serum detected using the Pha-
diatop IgE antibody addition, the elevated total
serum level of IgE, and the absolute eosinophil
count were measured, and we adopted cutoff val-
ues of >100 K/lL and >0.45 K/lL, respectively.
2.2. Establishing the diagnosis of AR
The recent Allergic Rhinitis and its Impact on
Asthma (ARIA) guideline states that the diagnosis
of AR should mostly be made through a combina-
tion of the physician’s clinical judgment and the
available diagnostic investigations [2]. In the pre-
sent study, AR diagnosis was mainly based on three
symptoms (sneezing and nasal itch, watery rhinor-
rhea, and nasal blockade); supportive findings of
physical signs, if they existed (indicating active dis-
ease); and an increased level of total serum IgE
antibody and/or identified sensitization to inhalant
allergens based on serum allergen-specific IgE anti-
body measurements.2.3. Statistical analysis
The statistical analysis was performed using the
software STATA for Macintosh version 13.0 (Stata
Corporation, College Station, TX, USA). Descriptive
data are presented as the means and standard devi-
ations for continuous variables when normally dis-
tributed, and as medians and interquartile ranges
when skewed. Categorical variables are presented
as counts and percentages. Comparisons of demo-
graphics, clinical and laboratory values between
the OSA and the non-OSA groups were also per-
formed using Student t test for continuous vari-
ables and the Chi-square test followed by the
Fisher’s exact test for some categorical variables.
A p value of 0.05 was adopted as the level of statis-
tical significance.3. Results
A total of 177 patientswith sleep-related complaints
were interviewed and screened for OSA during the
study period. Only 157 patients completely filled
out their questionnaires and thus were included in
the study [i.e., 20 (11.3%) patients were excluded].
In all, 97 patients were identified as suffering from
OSA (61.8%), 63.0% (n = 65) of whom were males,
with a mean age of 48.9 ± 11.9 years and a mean
body mass index (BMI) of 42.5 ± 17.1 kg/m2. The
non-OSA group comprised 38.2% (n = 60) of
the studied cohort, 55.0% (n = 33) of whom were
males, with a mean age of 39.5 ± 14 years and a
mean BMI of 29.1 ± 7.1 kg/m2. The final diagnoses
of the non-OSA group were as follows: insomnia,
16 cases; narcolepsy, four cases; restless legs
syndrome, three cases; habitual snoring, 12 cases;
poor sleep hygiene, 24 cases; and severe kyphosis,
one case.
Smokers constituted 17.2% (n = 27) of the sam-
ple and were slightly more frequent in the non-
OSA group compared with the OSA group (20.0%,
n = 12 vs. 15.5%, n = 15). Significant differences in
age, BMI, and the frequency of ex-smokers were
observed between the OSA and the non-OSA groups
(Table 1).
The medians of sleep parameters, namely, the
AHI and the percentage of sleep time with O2
saturation <90.0%, were significantly higher in the
OSA group. However, both groups seemed to be
sleepy because their mean ESS scores were >10,
although ESS scores and snoring were significantly
higher in the OSA group compared with the non-
OSA group. The most commonly encountered
comorbidities in our sample were AR, BA, hyper-
tension (HTN), gastroesophageal reflux disease
Table 1 Demographic data and clinical characteristics of study participants.
Characteristic Overall
mean ± SD n (%)
Non-OSA
mean ± SD n (%)
OSA
mean ± SD n (%)
p
Patients (No. (%)) 157 (100.0) 60 (38.2) 97 (61.8) NA
Age (y) 45.3 ± 13.5 39.5 ± 14 48.9 ± 11.9 0.01
Gender:
Male 96 (61.2) 33 (55.0) 63 (65.0) 0.21
Female 61 (38.9) 27 (45.0) 34 (35.1)
Smokers 27 (17.2) 12 (20.0) 15 (15.5) 0.46
Ex-smokers 49 (31.2) 13 (21.7) 36 (37.1) 0.04
Snoring:
Yes 122 (77.7) 34 (56.7) 88 (90.7) 0.01
No 23 (14.7) 18 (30.0) 5 (5.2)
Unknown 12 (7.7) 8 (13.3) 4 (4.1)
AHI (median, IQR) 11.2 (1.7–32.4) 0.4 (0.0–2.8) 26.8 (12.4–45.7) 0.01
% of sleep time with O2 saturation
below 90%, median (IQR)
1.4 (0.0–25.9) 0 (0–0.5) 7.6 (0.9–45.5) 0.01
Weight (kg) 97 ± 29.2 78.3 ± 18.5 108.5 ± 28.8 0.01
Height (cm) 164 ± 10.5 164 ± 10.3 164 ± 10.7 0.97
BMI (kg/m2) 37.4 ± 15.6 29.1 ± 7.1 42.5 ± 17.1 0.01
Neck circumference (inches) 15.9 ± 2 14.8 ± 1.7 16.6 ± 1.9 0.01
ESS score 12 ± 6.1 10.4 ± 6.1 12.9 ± 6 0.01
BQ score
High risk 120 (76.4) 32 (53.3) 88 (90.7) 0.01
Low risk 37 (23.6) 28 (46.7) 9 (9.3)
Allergic rhinitis 86 (54.8) 35 (58.3) 51 (52.6) 0.50
Bronchial asthma 81 (51.6) 33 (55.0) 48 (49.5) 0.50
Diabetes mellitus 52 (33.1) 16 (26.7) 36 (37.1) 0.18
Hypertension 72 (45.9) 17 (28.3) 55 (56.7) 0.01
Stroke 10 (6.4) 2 (3.3) 8 (8.3) 0.22
IHD 23 (14.7) 3 (5.0) 20 (20.6) 0.01
GERD 70 (44.6) 20 (33.3) 50 (51.6) 0.03
COPD 10 (6.4) 2 (3.3) 8 (8.3) 0.32
AHI, apnea-hypopnea index; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CI: Confidence interval; ESS,
Epworth Sleepiness Scale; GERD, gastroesophageal reflux disease; IHD, ischemic heart disease; SD, standard deviation.
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were significantly more frequent among OSA
patients (Table 1).
AR was encountered in 51 patients with OSA
(52.6%). However, in the non-OSA group, AR was
found in 36 participants (60.0%), which was not sig-
nificantly different from the rate in the OSA group
(p = 0.3), suggesting a high prevalence of AR among
patients attending the sleep clinic.
The OSA group was further divided into two
groups according to the presence (AR-OSA) or
absence (non-AR-OSA) of AR. Some of the sleep
parameters (snoring, BQ score, and AHI) were
slightly higher in the AR-OSA group compared with
the non-AR-OSA group, but this difference was not
significant (Table 2). However, there was a ten-
dency toward increased OSA severity (althoughnot statistically significant) among the AR-OSA
group compared with the non-AR-OSA group, as
indicated by the AHI [Pearson’s Chi-square test 2
(3) = 1.7114, p = 0.63] (Fig. 1). Also, Fig. 1 demon-
strated that, although there is a tendency of a link
between severity of OSA and AR, this association
was not significant.
Regarding atopy parameters, 59 individuals
(37.6%) had elevated total IgE (>100 K/lL), 36
(37.1%) of whom had OSA. Eosinophil counts were
elevated (>0.45 K/lL) in only 18 (11.5%) individu-
als, of whom 11 (11.3%) had OSA. Close to half of
the non-OSA and OSA groups [27 (45.0%) vs. 40
(41.2%)] had a positive Phadiatop test, with a
slightly higher percentage in the non-OSA group.
However, no statistically significant differences
were found (Table 3).
Table 2 Sleep parameters in obstructive sleep apnea (OSA) patients with and without allergic rhinitis (AR).
Sleep parameter Overall Nonallergic rhinitis Allergic rhinitis p
No. of patients 97 (100) 46 (47.4) 51 (52.6) NA
Snoring:
Yes 88 (90.7) 43 (93.5) 45 (88.2) 0.61
No 5 (5.2) 2 (4.4) 3 (5.9)
Unknown 4 (4.1) 1 (2.2) 3 (5.9)
ESS score 12.9 ± 6 13.3 ± 6.4 12.4 ± 5.6 0.45
BQ score:
High risk 88 (90.7) 42 (91.3) 46 (90.2) 0.85
Low risk 9 (9.3) 4 (8.7) 5 (9.8)
AHI 26.8 (12.4–45.7) 24.2 (11.2–44.7) 30.3 (15.6–46.6) 0.33
% of sleep time with O2
saturation 690%, median (IQR)
1.4 (0.0–25.9) 8.0 (0.9–49.8) 7.6 (0.6–37.4) 0.76
Data are presented as n (%), mean ± SD, or median (IQR).
BQ, Berlin questionnaire: high risk indicates the clinical probability of obstructive sleep apnea (OSA) is high; low risk indicates a low
clinical probability of OSA; ESS, Epworth sleepiness scale; IQR, interquartile ranges; SD, standard deviation.
Allergic rhinitis and atopic markers in obstructive sleep apnea 414. Discussion
The main outcome of this study was a high fre-
quency of OSA (61.8%) within the study population,Fig. 1 Frequency of allergic rhinitis (AR) among
obstructive sleep apnea (OSA) groups. Pearson’s Chi-
square test 2 (3) = 1.7114, p = 0.63. Obstructive sleep
apnea (OSA) severity: Normal (AHI = 1–4.9), Mild
(AHI = 5–14.9), Moderate (AHI = 15–29.9), Severe
(AHIP 30), where AHI is the apnea-hypopnea index.
AR = allergic rhinitis.
Table 3 Laboratory atopy parameters.
Parameter Overall
No. of patients 157 (100)
Total IgE >100 K/lL 59 (37.6)
Eosinophil count >0.4 K/lL 18 (11.5)
Positive Phadiatop test 67 (42.7)
Data are presented as n (%).
IgE, immunoglobulin E; OSA, obstructive sleep apnea.along with a high prevalence of AR (52.6%) among
the OSA patients and non-OSA individuals (58.0%).
However, a statistically significant difference in
the frequency of AR among patients with OSA com-
pared to those without OSA was not found in our
cohort. Although, we showed a trend of an
increased AHI among patients in the AR-OSA group
compared with those in the non-AR-OSA group, this
trend was not statistically significant. However, we
demonstrated that patients in the AR-OSA group
were more likely to have severe OSA compared
with those in the non-AR-OSA group (57.8% com-
pared with 42.2%).
The high frequency of OSA detected among
patients referred to the sleep clinic in this study
is not unusual and has been reported previously.
One systematic review revealed that up to 90% of
patients referred due to sleep complaints had
OSA [15]. This feature is particularly common
among those with comorbidities such as HTN, dia-
betes, and GERD, which were also common in our
study population [16].
Although there was no significant difference
between the prevalence of AR among those with
or without OSA in our cohort sample, we suspect
that the prevalence of AR in the non-OSA group
does not represent the actual frequency of AR inNon-OSA OSA p
60 (38.2) 97 (61.8) NA
23 (38.3) 36 (37.1) 0.88
7 (11.7) 11 (11.3) 0.95
27 (45) 40 (41.2) 0.64
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general population in Saudi Arabia is not known.
Nevertheless, a 52.6% prevalence of AR among
OSA patients is very high compared to the preva-
lence of AR in the general population elsewhere.
Studies from Europe and North America have
reported that the prevalence of AR among children
and adults ranges from 10.0% to 30.0% [17,18]. In
the Middle Eastern population, the data are more
limited; however, it was recently reported that
one tenth of this population suffers from AR [19].
In Saudi Arabia, there is no extant data on the
prevalence of AR among Saudi adults; however,
there are reports of nearly one quarter of Saudi
children suffering from AR, with an increasing
trend over the past decade [20]. Surprisingly, of
the 60 patients who were found to be OSA-free in
our study, 35 (58.3%) were concurrently suffering
from AR. This may be suggestive of AR being highly
prevalent in the Saudi population, however, one
limitation to keep in mind is that our study was
hospital-based. Furthermore, the mean age of the
AR group in our study was middle-aged; because
the symptoms of AR tend to decline with age, it
is unlikely that the prevalence of AR in middle-
aged adults is higher than that in children. A plau-
sible explanation for the very high prevalence of AR
among non-OSA cases in our study could be the fact
that patients with AR are likely to have disturbed
sleep – even without OSA – which may result in
more frequent visits to sleep clinics. This is a
potential hypothesis which presents a limitation
to our study and emphasizes the importance of
conducting future general population-based stud-
ies. Therefore, although our study showed no sig-
nificant association between AR and OSA when
compared with the non-OSA group, these results
should be interpreted with caution, taking into
account the aforementioned limitations.
The link between the two conditions has been
discussed in the literature before and it has been
suggested that treating AR may improve symptoms
of OSA. In 1997, Young et al. [21] described AR as a
potential risk factor for OSA in a population-based
study. The authors found that the study partici-
pants with nasal congestion due to allergy were
1.8 times more likely to have moderate to severe
OSA than those without nasal congestion; however,
a linear relationship between nasal obstruction and
the severity of sleep-disordered breathing was not
found. Subsequently, several studies that investi-
gated AR as a risk factor for OSA produced similarly
variable outcomes. In fact, many studies have sug-
gested that there is an increased prevalence of AR
among patients with OSA. Gu¨l et al. [3] investi-gated 80 patients with OSA and found that 23.0%
had AR. In another study, Canova et al. [4] also
reported an increased prevalence of perennial AR
in OSA patients compared with patients with
chronic obstructive pulmonary disease (11.0% vs.
2.3%). Based on subjective criteria, Le´ger et al.
[22] reported that OSA was more prevalent in AR
patients than in controls. However, our study failed
to demonstrate this positive correlation between
AR and OSA. This discrepancy with the previous
studies may be attributed to different methodolo-
gies and the fact that there was a high prevalence
of AR among our cohort patients. Interestingly, one
recent study reported a significant positive correla-
tion between clinical control of rhinitis symptoms
and clinical control of OSA [23]. Although the
effect of treating AR on the control of OSA was
not addressed in our study, we reported a trend
of a slightly increased AHI (not statistically signifi-
cant) among patients with AR and OSA in our study.
In addition, when we classified the severity of the
AR-OSA and non-AR-OSA groups as severe, moder-
ate, or mild OSA, we noticed that more patients
with severe OSA were identified in the former
group than in the latter group.
In the present study, we were especially inter-
ested in the results of sensitization to common
inhalant allergens and used Phadiatop to confirm
atopy. Phadiatop tests were found to be positive
in 41.2% of the OSA group and nearly half of the
non-OSA group, but these percentages were not
significantly different. These results seem to be
consistent with several studies assessing the same
association in patients undergoing an SPT. For
example, Rochford et al, found that 74.0% of sub-
jects with OSA undergoing an SPT were atopic
[24]. Similarly, in a more recent study, investiga-
tors found that atopy based on the SPT was present
in approximately 72.5% of subjects who were at
high risk of OSA according to the BQ. Of those,
69.2% who were confirmed to have OSA via PSG
were found to be atopic as well [25]. In addition,
allergic sensitization was also linked to snoring in
children [26]. Previous epidemiologic studies
revealed patients with asthma to be at a higher risk
of OSA than those without asthma [27,28]. Further-
more, several studies demonstrated that OSA is
more common in moderate to severe as well as dif-
ficult to treat asthma. In fact, BA and AR often
coexist as the one airway hypothesis implies repre-
senting a spectrum of the same disease [29]. How-
ever, only recently Teodorescu et al, in a
population-based study reported that asthma is
associated with an increased risk of new-onset
OSA [30]. In spite of that, our study failed to
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compared with non-OSA patients. Again this dis-
crepancy could be explained by the different
methodologies and different cohort patients used
in our study.
To the best of our knowledge, this study is the
first of its kind in the region. Although it was sug-
gested that AR may be linked to OSA, our study
failed to demonstrate a significant difference in
the prevalence of AR between the OSA and
non-OSA groups. However, our study had certain
limitations, including the selection bias and the
relatively small sample size, which could bias the
association toward the null. In addition, our study
failed to demonstrate a significant association
between atopic markers with OSA. Nevertheless,
our study demonstrated a trend of increased sever-
ity of OSA among AR patients, but failed to reach
statistical difference. This warrants further investi-
gation in a larger study, which ideally should be
population-based rather than conducted among
patients attending a sleep clinic.
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